Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Solid Tumors
Interventions
BIOLOGICAL

mRNA-4157

IM injection

BIOLOGICAL

Pembrolizumab

Intravenous infusion

BIOLOGICAL

SoC Treatment

Intravenous infusion

Trial Locations (34)

10016

RECRUITING

NYU Langone Medical Center, New York

15219

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

20037

RECRUITING

The George Washington Cancer Center, Washington D.C.

27710

RECRUITING

Duke Cancer Institute, Durham

32806

RECRUITING

Orlando Health Cancer Institute, Orlando

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI, Oncology Partners, Nashville

48202

RECRUITING

Henry Ford Cancer, Detroit

75390

RECRUITING

UT Southwest Medical Center, Dallas

85721

RECRUITING

University of Arizona, Tucson

90025

RECRUITING

Angeles Clinic and Research Institute, Los Angeles

33612-9416

RECRUITING

H Lee Moffitt Cancer Center and Research Institute, Tampa

02114

RECRUITING

Massachusetts General Hospital, Boston

07601

RECRUITING

Hackensack University Medical Center, John Theurer Cancer Center, Hackensack

44195-0001

RECRUITING

The Cleveland Clinic Foundation, Cleveland

97213-2933

WITHDRAWN

Providence Portland Medical Center, Portland

Unknown

RECRUITING

Chris O'Brien Lifehouse, Camperdown

RECRUITING

St Vincents Hospital Sydney, Darlinghurst

RECRUITING

Scientia Clinical Research Ltd, Randwick

RECRUITING

Westmead Hospital-Cnr Hawkesbury and Darcy Road, Westmead

RECRUITING

The Queen Elizabeth Hospital, Woodville South

RECRUITING

PASO Medical, Frankston

RECRUITING

One Clinical Research Perth, Perth

RECRUITING

National Cancer Center East, Chiba

RECRUITING

Kindai University Hospital, Osaka

RECRUITING

National Cancer Center Hospital, Tokyo

RECRUITING

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo

RECRUITING

NHS Tayside, Dundee

RECRUITING

Imperial College Healthcare NHS Trust, London

RECRUITING

Royal Mardsen London, London

RECRUITING

University College of London, London

RECRUITING

The Christie NHS Foundation Trust, Manchester

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

RECRUITING

Royal Mardsen Sutton, Sutton

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

ModernaTX, Inc.

INDUSTRY